Dr. John Cush RheumNow
4 years ago
The 2022 ACR abstracts are published and posted for you. Let the Learning begin! https://t.co/fNkzQVXHJx https://t.co/9AuamLB0Ha
Dr. John Cush RheumNow
4 years ago
A longitudinal study of 506 ANCA-associated vasculitis (AAV) pts showed pts w/ negative ANCA serologies within 180 days of induction had signif lower risk of relapse (HR 0.55; 0.38 to 0.81) but not for ESRD or death within 5 years. https://t.co/qFb2Usov8L https://t.co/faogbabc2W
Dr. John Cush RheumNow
4 years ago
Immunosuppresive (IST; MMF or AZA) withdrawl in 96 stable Lupus Nephritis pts also on HCQ. After 2 years, Relapse occurred in 12.5% w/ IST continued & 27.3% with IST D/C (Not noninferior). Less Severe SLE flares (renal & extrarenal) w/ IST continuation https://t.co/TM6Ng3vzeS https://t.co/UNBdg1Oh6z
Dr. John Cush RheumNow
4 years ago
CD19 CAR T Cell Therapy in SLE
Dr. Jack Cush reviews the news, journal reports, ACR and FDA announcements from the past week on RheumNow.
https://t.co/OJ8WFyB3jc https://t.co/11wanMBjkO
Dr. John Cush RheumNow
4 years ago
Anti-CD19 CAR T cell therapy for refractory #SLE published in Nature Medicine. 5 pts (22yrs) w/ refractory dz, active SLE (SLEDAI=16). Autologous pt T cells transduced to CD19 CAR Tcells, and lead to remission in 5/5 w/in 3 mos & maintained median 8 mos https://t.co/0epnffCNEN https://t.co/IMRzhOzgei
The big news this week: the approval of deucravacitinib (a new class of drug?) for psoriasis; the 2022 ACR guidance on glucocorticoid-induced osteoporosis; a national poll of older adults over the age of 50 who claimed self-reported or doctor-diagnosed arthritis; and much more. Let's review these and other news, journal reports and announcements from this past week.
Dr. John Cush RheumNow
4 years ago
Lupus (LUMEN) registry of 440 SLE compared to non-SLE pts, shows lupus pts have less screening for cervical cancer (HR 0.75), but SLE has more screening for HTN (HR 1.35), DM (HR 2.46), hyperlipidemia (HR 3.19) & Influenza & pneumovax vaccines https://t.co/e5ZGJswVds https://t.co/WQmhM0OZgl
Dr. John Cush RheumNow
4 years ago
Open label, noninferiority study TNFi withdrawal in 64 PsA & 58 axSpA pts. 2/3 tapered by dz activity T2T strategy (N=81) & 1/3 continued TNFi. At 12 mos. LDA seen in 69% w/ Tapering (~avg 53% dose) vs 73% no-tapering group (91% dose) https://t.co/K6WFaesyRt https://t.co/zqo6nVGtqW
Dr. John Cush RheumNow
4 years ago
Ischemic Forearm Exercise Test - used by McArdle, notes absence of elevated blood lactate levels during exercise w/ myophosphorylase deficiency (McArdle Dz). Deficiency impairs impairs glycogen metabolism & Nl lactate production in muscle https://t.co/t4PS1ghj5d https://t.co/YUDM1GCOfn
Dr. John Cush RheumNow
4 years ago
534 PsA & 470 AS pts (SERENA study) on Secukinumab for avg of ~88wks - 5.8% PsA & 8.9% AS pts had sudden stop of SEC (for avg ~25wks) (reasons? Mostly AE 58% or pt decision 10%). While TJC & SJC increased, dz control returned w/ restarting SEC https://t.co/GFxj3b06Ra https://t.co/B2ubakq8Ql
Findings of a new study suggest a causal effect between inflammatory bowel disease (IBD) and psoriasis (PSO) as well as psoriatic arthritis (PsA), but not vice versa.
A systematic review suggests that low-dose methotrexate (MTX) use is associated with an increased melanoma risk, but the absolute risk increase could be considered negligible.
Dr. John Cush RheumNow
4 years ago
2022 Univ of Michigan Natl Poll on Healthy Aging finds that 70% of older adults reported joint pain (more in Women 75% vs 65%M). 30% have a HCP dx of #OA, 8% RA, 7% gout or pseudogout & 5% w/ another kind of arthritis
https://t.co/yno8RgCRQS https://t.co/yTMLHsbGOU
Healio Rheumatology HealioRheum
4 years ago
New York is the best state for patients with #rheumatic diseases to live in, while Wyoming was ranked worst in the United States #RheumTwitter
https://t.co/ulYd0uNKZO
